First report on prostate displacements immediately before and after treatment relative to the position during VMAT delivery

[1] Hirvikoski PP, Kumpulainen EJ, Johansson RT. CNF combination as adjuvant treatment in breast cancer patients is well tolerated. Anti-Cancer Drugs 1997;/8:/376 8. [2] Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Breast Cancer Res Treat 1997;/44:/269 74. [3] Kumpulainen EJ, Hirvikoski PP, Pukkala E, Johansson RT. Cancer risk after adjuvant chemoor chemohormonal therapy of breast cancer. Anti-Cancer Drugs 1998;/9:/131 4. [4] Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;/304:/ 10 5. [5] Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;/ 75:/301 5. [6] Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;/80:/1763 6. [7] Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;/91:/2246 57. [8] Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindmar H, Malmström P, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported highdose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;/356:/1384 91.